References
- Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996; 38: 409–24.
- Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867–78.
- Coetzee JN, Datta N, Hedges RW. R-factors from Proteus rettgeri. J Gen Microbiol 1972; 72: 543–52.
- Vahaboglu H, Dodanli S, Eroglu C, Ozturk R, Soyletir G, Yildirim I, et al. Characterization of multiple-antibiotic-resistant Salmonella typhimurium strains: molecular epidemiology of PER-1-producing isolates and evidence for nosocomial plasmid exchange by a clone. J Clin Microbiol 1996; 34: 2942–6.
- French GL, Shannon KP, Simmons N. Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase. J Clin Microbiol 1996; 34: 358–63.
- Reguera JA, Baquero F, Perez-Diaz JC, Martinez JL. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli. J Antimicrob Chemother 1991; 27: 569–75.
- Bonomo RA, Rudin SA, Shlaes DM. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases. FEMS Microbiol Lett 1997; 148: 59–62.
- Livermore DM, Seetulsingh P. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin [comment] [see comments]. J Antimicrob Chemother 1991; 27: 761–7.
- Wu PJ, Shannon K, Phillips I. Effect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics. Antimicrob Agents Chemother 1994; 38: 494–8.
- Stapleton P, Wu PJ, King A, Shannon K, French G, Phillips I. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother 1995; 39: 2478–83.